New combo therapy shows promise for Hard-to-Treat colorectal cancer
NCT ID NCT07512674
First seen Apr 07, 2026 · Last updated May 14, 2026 · Updated 5 times
Summary
This study tests a new treatment for people with advanced colorectal cancer that has spread to the liver, lungs, or abdomen and cannot be removed by surgery. The treatment combines a short course of radiation with immunotherapy (tislelizumab), chemotherapy (CAPOX), and a targeted drug (bevacizumab). The goal is to see if this combination can shrink tumors and improve outcomes. The study involves 33 participants and is currently active but not recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PATIENTS WITH INITIALLY UNRESECTABLE MSS-TYPE ADVANCED COLORECTAL CANCER WITH LIVER AND/OR LUNG AND PERITONEAL METASTASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
Hangzhou, Zhejiang, China
Conditions
Explore the condition pages connected to this study.